Rhumbline Advisers Neoleukin Therapeutics, Inc. Transaction History

Rhumbline Advisers

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$0.92 - $2.25 $38,149 - $93,300	-41,467 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$1.72 - $5.23 $5,634 - $17,133	-3,276 Reduced 7.32%	41,467 $78,000
Q4 2021 Feb 10, 2022	SELL	$4.65 - $7.75 $2,748 - $4,580	-591 Reduced 1.3%	44,743 $216,000
Q3 2021 Nov 12, 2021	SELL	$6.05 - $9.66 $30,994 - $49,488	-5,123 Reduced 10.15%	45,334 $328,000
Q2 2021 Aug 05, 2021	BUY	$9.23 - $13.12 $140,794 - $200,132	15,254 Added 43.33%	50,457 $466,000
Q1 2021 May 06, 2021	SELL	$11.26 - $15.78 $25,672 - $35,978	-2,280 Reduced 6.08%	35,203 $433,000
Q4 2020 Feb 10, 2021	BUY	$10.17 - $14.56 $34,984 - $50,086	3,440 Added 10.1%	37,483 $529,000
Q3 2020 Nov 12, 2020	SELL	$9.68 - $17.01 $17,414 - $30,600	-1,799 Reduced 5.02%	34,043 $409,000
Q2 2020 Aug 13, 2020	BUY	$9.95 - $17.05 $356,627 - $611,106	35,842 New	35,842 $595,000

199K

Ticker NLTX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 42,579,900
Description
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of vario...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.